Avadel Pharmaceuticals (AVDL) Competitors $11.05 -0.10 (-0.86%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVDL vs. PCVX, PTCT, ZLAB, ACAD, ACLX, AKRO, VKTX, MTSR, SWTX, and SRRKShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Vaxcyte (PCVX), PTC Therapeutics (PTCT), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), Metsera (MTSR), SpringWorks Therapeutics (SWTX), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Its Competitors Vaxcyte PTC Therapeutics Zai Lab ACADIA Pharmaceuticals Arcellx Akero Therapeutics Viking Therapeutics Metsera SpringWorks Therapeutics Scholar Rock Vaxcyte (NASDAQ:PCVX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings. Do analysts prefer PCVX or AVDL? Vaxcyte presently has a consensus target price of $136.50, indicating a potential upside of 313.24%. Avadel Pharmaceuticals has a consensus target price of $18.33, indicating a potential upside of 65.85%. Given Vaxcyte's stronger consensus rating and higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, PCVX or AVDL? Avadel Pharmaceuticals has higher revenue and earnings than Vaxcyte. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$3.99-8.28Avadel Pharmaceuticals$169.12M6.32-$48.83M-$0.27-40.94 Does the media prefer PCVX or AVDL? In the previous week, Vaxcyte had 1 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 6 mentions for Avadel Pharmaceuticals. Vaxcyte's average media sentiment score of 1.33 beat Avadel Pharmaceuticals' score of 0.89 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in PCVX or AVDL? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, PCVX or AVDL? Vaxcyte has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Is PCVX or AVDL more profitable? Vaxcyte has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -13.58%. Vaxcyte's return on equity of -17.12% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -17.12% -16.26% Avadel Pharmaceuticals -13.58%-36.07%-16.30% SummaryVaxcyte beats Avadel Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$2.50B$5.46B$9.56BDividend YieldN/A1.77%4.71%4.14%P/E Ratio-40.999.0928.7523.86Price / Sales6.32688.51438.0495.35Price / CashN/A159.4135.6858.35Price / Book14.365.188.155.61Net Income-$48.83M$31.61M$3.25B$265.26M7 Day Performance3.31%-1.31%-0.97%-1.02%1 Month Performance23.85%4.75%5.25%4.81%1 Year Performance-33.53%2.91%28.36%23.32% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals2.8232 of 5 stars$11.05-0.9%$18.33+65.9%-30.9%$1.07B$169.12M-40.9970PCVXVaxcyte2.1026 of 5 stars$33.72+2.1%$136.50+304.8%-53.6%$4.26BN/A0.00160Positive NewsGap DownPTCTPTC Therapeutics4.5055 of 5 stars$52.25+0.2%$69.38+32.8%+64.9%$4.13B$806.78M7.191,410Upcoming EarningsInsider TradeZLABZai Lab2.4248 of 5 stars$38.05+3.3%$54.28+42.6%+124.0%$4.09B$398.99M0.001,869Positive NewsUpcoming EarningsGap UpACADACADIA Pharmaceuticals3.9108 of 5 stars$24.04+2.2%$28.13+17.0%+28.4%$3.94B$957.80M34.60510ACLXArcellx2.6517 of 5 stars$72.08+1.3%$114.31+58.6%+41.0%$3.92B$107.94M0.0080News CoveragePositive NewsAnalyst UpgradeAnalyst RevisionAKROAkero Therapeutics4.0571 of 5 stars$48.62+0.5%$81.57+67.8%+108.2%$3.86BN/A0.0030News CoveragePositive NewsUpcoming EarningsAnalyst ForecastVKTXViking Therapeutics3.9728 of 5 stars$33.98+4.0%$86.92+155.8%-34.6%$3.67BN/A0.0020MTSRMetseraN/A$34.44-1.3%$55.00+59.7%N/A$3.67BN/A0.0081SWTXSpringWorks Therapeutics0.3797 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoverageSRRKScholar Rock4.3481 of 5 stars$36.99+1.7%$44.14+19.3%+340.8%$3.45B$33.19M0.00140Earnings ReportGap Down Related Companies and Tools Related Companies PCVX Competitors PTCT Competitors ZLAB Competitors ACAD Competitors ACLX Competitors AKRO Competitors VKTX Competitors MTSR Competitors SWTX Competitors SRRK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVDL) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVDL Stock Alerts